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Background: High-pressure ventilation induces barotrauma and pulmonary inflammation, thus
leading to ventilator-induced lung injury (VILI). By limiting the pulmonal inflammation cascade
the anti-inflammatory cytokine interleukin (IL)-10 may have protective effects. Via inhalation,
IL-10 reaches the pulmonary system directly and in high concentrations.
Methods: Thirty six male, anesthetized and mechanically ventilated SpragueeDawley rats
were randomly assigned to the following groups (nZ 9, each): SHAM: pressure controlled
ventilation with pmaxZ 20 cmH2O, PEEPZ 4; VILI: ventilator settings were changed for
20 min to pmaxZ 45 cmH2O, PEEPZ 0; IL-10high: inhalation of 10 mg/kg IL-10 prior to induction
of VILI; and IL-10low: inhalation of 1 mg/kg IL-10 prior to induction of VILI. All groups were venti-
lated and observed for 4 h.
Results: High-pressure ventilation increased the concentrations of macrophage inflammatory
protein (MIP)-2 and IL-1b in bronchoalveolar lavage fluid (BALF) and plasma. This effect was
reduced by the inhalation of IL-10 (10 mg/kg). Additionally, IL-10 increased the animal survival
time (78% vs. 22% 4-h mortality rate) and reduced NO-release from ex vivo cultured alveolar
macrophages. Moreover, VILI-induced pulmonary heat shock protein-70 expression was reduced
by IL-10 aerosol in a dose-dependent manner. Similarly, the activation of matrix metalloprotei-
nase (MMP)-9 in BALF was reduced dose-dependently by IL-10. IL-10-treated animals showed
a lower macroscopic lung injury score and less impairment of lung integrity and gas exchange.)89 7095 4551; fax: þ49 (0)89 7095 8885.
.uni-muenchen.de (S. Hoegl).
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464 S. Hoegl et al.Conclusions: Prophylactic inhalation of IL-10 improved survival and reduced lung injury in exper-
imental VILI. Results indicate that this effectmaybemediated by the inhibition of stress-induced
inflammation and pulmonary biotrauma.
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Mechanical ventilation plays a crucial role in the treatment
of critically ill patients. However, mechanical ventilation
itself can cause lung damage and impairment of gas
exchange. Especially patients who need high ventilation
pressures to maintain proper oxygenation and CO2-elimi-
nation are at risk of structural lung damage and subsequent
increased systemic cytokine levels and mortality rates.1
The concept of ventilator-induced lung injury (VILI)
contains not only barotrauma, with alveolar disruption,
capillary leakage and lung edema, but also biotrauma, i.e.
the release of proinflammatory cytokines and mediators by
pulmonary cells like alveolar macrophages or epithelial
cells.2 Mechanical ventilation, and especially high tidal
volumes and high inspiratory pressures,3 can trigger
a complex pro- and anti-inflammatory immune reaction.4
Furthermore, this pulmonary proinflammatory response is
not confined to the lungs but also extends to systemic
circulation, thus contributing to the development of
systemic inflammatory response (SIRS) and multiple organ
dysfunction syndrome (MODS).5
Modulating this imbalance between pro- and anti-
inflammatory mediators in the lung might be a therapeutical
approach. With aerosol therapy, anti-inflammatory drugs
can be delivered directly to the lung parenchyma. IL-10 is
a cytokine with potent anti-inflammatory properties due to
its ability to decrease the synthesis and secretion of
proinflammatory cytokines.6 In a model of lipopolysaccha-
ride (LPS)-induced endotoxemia, our group has already
demonstrated that inhaled IL-10 attenuates pulmonary and
systemic TNF-a, IL-1b and IL-6 concentrations.7 In an in
vitro experiment, Lee et al.8 showed that IL-10 protects
cultured rat type II epithelial cells from injury induced
by mechanical stretch by decreasing apoptosis and IL-8
production. In the present study, we therefore aimed
to evaluate the intrapulmonary and systemic anti-




All animal experiments were approved by the governmental
board for the care and use of animal subjects (Regierung-
spraesidium Darmstadt, Germany) and performed according
to the ‘‘Guide for the Care and Use of Laboratory Animals’’
(National Academic Press, Washington D.C., 1996). Male
SpragueeDawley rats (nZ 36) were obtained from Janvier
(Le Genest-St-Isle, France; mean body weight SD,
590 40 g). Rats were anesthetized initially by an i.p.injection of pentobarbital (Narcoren, Merial, Hallbergmoos,
Germany; 50 mg/kg) and fentanyl (Janssen-Cilag, Neuss,
Germany; 0.05 mg/kg), weighed and then placed supine on
a heating pad. Following tracheotomy, animals were venti-
lated with an infant ventilator (Stephanie, Stephan, Gack-
enbach, Germany) using pressure controlled ventilation
(PCV), with the following standard ventilator adjustments:
peak airway pressure (pmax)Z 20 cmH2O; positive end-
expiratory pressure (PEEP)Z 4 cmH2O; fZ 30/min; fraction
of inspired oxygen (FiO2)Z 0.21; inspiratory to expiratory
time ratio (I:E)Z 1:2. The body temperature was measured
rectally and kept constant at 37.0e38.0 C throughout the
experiment. Fluid-filled polyurethane catheters
(IDZ 0.58 mm; ODZ 0.96 mm; SIMS Portex Ltd, Hythe, UK)
were inserted into the right femoral vein and artery for
infusion of anesthetics (pentobarbital (5e10 mg/kg/h),
fentanyl (2.5e5.0 mg/kg/h)), measurement of blood pres-
sure and blood gas analysis, respectively.
Experimental groups
After a stabilization time of 15 min, the rats were randomly
assigned to the following groups (nZ 9, each; Fig. 1). In the
VILI group, animals received nebulized phosphate-buffered
saline (PBS (Serva, Heidelberg, Germany), the diluent of IL-
10) and afterwards mechanical lung damage was induced by
changing the ventilator settings for 20 min to
pmaxZ 45 cmH2O, PEEPZ 0 and I:EZ 1:1. This pressure
enhancement was done step-by-step over a period of 2 min
to avoid rapid changes in the systemic and pulmonary blood
circulation. After the induction of VILI, the ventilator
settings were reset stepwise to the standard ventilator
adjustments. Animals in the therapy groups received IL-10
(R and D Systems, Wiesbaden, Germany) aerosol directly
before the induction of VILI (IL-10high (10 mg/kg body
weight) and IL-10low (1 mg/kg body weight)). Animals of the
SHAM group received PBS aerosol and were ventilated for
the observation period of 4 h with the standard ventilator
adjustments. For the application of the aerosol, rats were
connected to a specifically designed small animal jet
nebulizer for 40 min, as described elsewhere (pmaxZ
15 cmH2O, PEEPZ 0, fZ 40, FiO2Z 0.25). The nebulizer
produces an alveolar aerosol with a deposition fraction of
approximately 4%.9
At the end of the protocol animals were exsanguinated
and blood samples were obtained. After thoracotomy and
inspection of the lung the accessory lobe was ligated and
the mechanical ventilation was terminated. Thereafter,
a bronchoalveolar lavage was performed with eight aliquots
of 10 mL of PBS. Every rinse with a 10-mL aliquot was
performed in a standardized way within 20 s. Subsequently,
the accessory lobe was divided into three parts. One part
was fixed in 10% buffered formalin for histological
Figure 1 Experimental protocol. Animals of the SHAM group received phosphate-buffered saline (PBS) aerosol and were venti-
lated for an observation time of 4 h (standard ventilator adjustments/pressure controlled ventilation (PCV)). In the VILI group,
animals received nebulized PBS previously to VILI induction. After the induction of VILI, the ventilator settings were reset stepwise
to the standard ventilator adjustments. Animals in the therapy groups received IL-10 aerosol directly before the induction of VILI
(IL-10high (10 mg/kg body weight) and IL-10low (1 mg/kg body weight)).
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liquid nitrogen and stored at 80 C.
Macroscopic lung injury score
We assessed the macroscopic lung damage according to the
classification described by Lim et al.10 Accordingly, the
ventral and dorsal surfaces of the lung were divided into
four quadrants and the presence and extent of hemorrhage
were examined. When more than half of the lung surface in
the quadrant showed hemorrhage, this was correlated with
a score of 2. When less than half of the lung surface was
affected, this was correlated with a score of 1. No visible
lung damage complied with a score of 0. This resulted in
a possible lung injury score from 0 (uninjured lung) to 16
(maximal lung damage).10
Isolation of BAL cells, BALF and lung tissue
The BALF obtained was centrifuged and the supernatant
was frozen and stored at 80 C. To analyze nitrite release
as readout for inducible nitric oxide synthase (iNOS) acti-
vation, the remaining cell pellet was resuspended and
seeded on polystyrene plates. After initial cultivation for
2 h, non-adherent cells were removed by washing.
Adherent cells were regarded as alveolar macrophages and
incubated at 37 C in 5% CO2 for 20 h. The nitrite concen-
tration in cell culture supernatants was determined by
Griess assay.11 For Western blotting, the lung samples were
homogenized in lysis buffer (150 mM NaCl, 1 mM CaCl2,
25 mM TrisCl, pH 7.4, 1% Triton X-100), supplemented with
protease inhibitor cocktail (Roche Diagnostics, Mannheim,
Germany), DTT, Na3VO4, PMSF (each 1 mM) and NaF
(20 mM). The tissue extract was cleared by centrifugation
and the supernatant was frozen and stored at 80 C. Total
protein concentrations of BALF samples and lung homoge-
nates were determined with the Bradford assay.12
Plasma samples and ELISA assay
Blood samples were centrifuged and the resulting plasma
was collected and frozen at 80 C. The BALF and plasmalevels of macrophage inflammatory protein-(MIP)-2 (Bio-
source, Camarillo, CA) and IL-1b (R and D Systems, Wies-
baden, Germany) were determined by ELISA according to
the manufacturer’s instructions.
Western blot analysis and SDSePAGE zymography
Western blot analysis of heat shock protein (HSP)-70
(StressGen, Ann Arbor, MI) in the lung homogenates was
performed using standard procedures. Gelatinolytic activity
of proteins from BALF (30 mL) was assessed as described
previously.13 Gelatinolytic activity of proteins was visual-
ized as lightened areas on an otherwise blue gel and their
migration properties were determined by a comparison
with prestained full-range rainbow protein markers
(Amersham Biosciences, Piscataway, NJ).
Statistics
Data are presented as median [semi-interquartile range
(semi-IQR)]. Statistical analysis was performed with Sigma
Stat (SPSS-Jandel 3.1 Scientific, San Jose, CA). Kaplane
Meier curves of survival were analyzed by the log-rank test
and adjusted for multiple comparisons with Bonferroni
correction. Differences between the groups were analyzed
using the KruskaleWallis one way analysis of variance on
ranks followed by a multiple comparison vs. the VILI group
(Dunn’s method). Statistical significance was accepted at
p< 0.05.
Results
Outcome and physiopathological evaluations
In the VILI group, only two out of nine animals survived the
whole observation period of 4 h, corresponding to
a mortality rate of 78%. Inhalation of 10 mg/kg IL-10 prior to
VILI induction improved significantly survival and decreased
the 4-h mortality rate to 22% (Fig. 2). In the IL-10low group
the 4-h mortality rate was 56% which failed to reach
statistical significance.
Figure 2 KaplaneMeier curve and analysis of survival. All
animals ventilated with the low-pressure regime (SHAM, nZ 9)
survived the observation period of 240 min, whereas only two
animals of the VILI-only group (20 min of ventilation with
a peak airway pressure of 45 cm H2O, PEEPZ 0; nZ 9) were
still alive 240 min post injury (log-rank test, p< 0.001).
Prophylactic administration of high-dose IL-10 aerosol signifi-
cantly improved survival (*p< 0.016).
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a rapid decline of paO2 and a rise of paCO2 after VILI (Table 1).
In addition, in contrast to the VILI group in the IL-10high
group tidal volume (VT) was not reduced after VILI induc-
tion. In the VILI group the mean arterial pressure (MAP)
declined over time and the animals became acidotic. It
seems that inhaled IL-10 was able to stabilize MAP and pH,
but did not prove significant. Only 1 h after VILI induction
the pH of the IL-10high group was significantly higher than
the pH in the VILI group.
Statistical tests of paO2, paCO2, VT, MAP and pH were
performed at the following time-points: baseline, 1 h and
2 h after VILI induction. Only two animals of the VILI group
survived 3 h after VILI induction; therefore we did not
perform statistical measurements at later time-points.
The grossmacroscopic appearanceof the lungs of IL-10high
animals was found to be less hemorrhagic and edematous as
compared to the lungs of VILI animals (lung injury score
SHAM: 0, VILI: 11.0 [0.5], IL-10high: 4.0 [0.5] [p< 0.029], IL-
10low: 9.0 [3.0]). Also, the histological changes in terms of
perivascular and interstitial edema, inflammatory cell infil-
tration, intra-alveolar hemorrhage and atelectasis were less
severe in IL-10-treated animals (Fig. 3).
Parameters of lung inflammation
Since this study focused on the evolving inflammatory
processes, only plasma, bronchoalveolar lavage fluid (BALF)
and lung probes from the animals that survived the critical
time period of 2 h after the induction of VILI were
collected. In this context, Chiumello et al.14 showed that
after the beginning of injurious ventilation, local and
systemic levels of proinflammatory cytokines increase over
time, with a high peak between 2 and 4 h.As a result, we achieved the following group sizes for the
subsequent measurements: SHAM, nZ 9; VILI, nZ 7; IL-
10high, nZ 8; IL-10low, nZ 4.
The protein content in the BALF was less elevated in IL-
10-treated animals as compared with the VILI animals
(SHAM: 245 [15], VILI: 1469 [286], IL-10high: 859 [308]
[p< 0.018], IL-10low: 939 [258]).
Nitrite accumulation in the supernatants of cultured
macrophages from the IL-10-treated animals (IL-10high) was
significantly lower than compared to VILI animals (16.9
[7.3] vs. 29.1 [9.5] [p< 0.045], SHAM: 5.2 [1.7], IL-10low:
18.2 [3.6]).
High-pressure ventilation augmented the MIP-2 and IL-1b
concentrations both in BALF and in plasma as detected by
ELISA (Fig. 4). Whereas the BALF and plasma concentrations
of IL-1b were reduced significantly only in the IL-10high-
treated animals, MIP-2 release was significantly inhibited by
both concentrations of nebulized IL-10.
Western blot analysis of the lung homogenates showed
that VILI induced the intrapulmonary HSP-70 expression and
IL-10 aerosol is able to prevent this induction (Fig. 5).
The zymogram of the BALF in SHAM animals displayed
only weak gelatinolytic bands for gelatinase A (MMP-2) and
gelatinase B (MMP-9). In contrast, animals ventilated with
high pressure displayed intense gelatinolytic bands for both
matrix metalloproteinases. Nebulized IL-10 reduced the
gelatinolytic activity of MMP-9 in the BALF (Fig. 6).Discussion
In the present study, 20 min of high-pressure ventilation in
healthy rats resulted in severe lung injury with a subse-
quently highmortality rate andpronouncedalterations in the
lung architecture and gas exchange. As demonstrated
previously, this is a result of pulmonary biotrauma, i.e.
a stretch-induced inflammatory reaction with release of
local and systemic mediators and activation of neutrophils
and alveolar macrophages.15,16 The prophylactic inhalation
of the anti-inflammatory cytokine IL-10 prior to the induction
of experimental VILI attenuated the biotrauma and thus
protected the lung against disintegration and pulmonary
failure. In addition, despite small group sizes and a short
observation time of 4 h, inhaled IL-10 resulted in improved
survival. It seems that in this model limiting the pulmonal
inflammation cascade by IL-10 aerosol has the impact to
prevent ventilator-induced lung injury almost completely.
IL-10 is a pluripotent cytokine with strong anti-inflam-
matory effects on numerous cell types, in particular
circulating and resident immune cells as well as epithelial
cells. IL-10 not only modifies the expression and activity of
proinflammatory cytokines, chemokines and adhesion
molecules, but also suppresses the expression of antigen-
presenting and costimulatory molecules in monocytes/
macrophages, neutrophils, and T cells.6 Because of its
ability to inhibit the inflammatory cascade simultaneously
on several levels, IL-10 was and is under investigation for
therapy of a variety of chronic inflammatory disorders,
including rheumatoid arthritis,17 inflammatory bowel
disease18 and psoriasis.19
The novelty and potential strength of our therapeutical
concept is the administration by inhalation which allows for
Table 1 Arterial partial pressures of oxygen (paO2) and carbon dioxide (paCO2), tidal volume (VT), mean arterial pressure
(MAP) and pH-value (pH).
Time after induction of ventilator-induced lung injury (VILI)
BL 1 h 2 h 3 h 4 h
paO2 [Torr]
SHAM 105.7 [5.3] 109.4 [5.9] 102.5 [9.0] 104.7 [8.6] 102.2 [10.9]
VILI 108.0 [5.0] 52.9 [12.1] 50.1 [10.1] 56.7 [4.2] 44.2 [7.3]
IL-10high 118.2 [5.0] 85.9 [8.3]* 82.8 [5.8]* 78.0 [4.9] 80.1 [7.8]
IL-10low 101.3 [2.7] 63.1 [11.2] 70.3 [9.1] 62.4 [12.6] 59.3 [9.4]
paCO2 [Torr]
SHAM 35.3 [4.0] 36.6 [3.9] 35.3 [4.8] 36.4 [5.0] 37.9 [2.5]
VILI 35.2 [3.2] 56.3 [4.5] 54.8 [5.0] 50.9 [1.4] 62.1 [1.6]
IL-10high 32.7 [2.2] 40.2 [4.5]* 42.7 [5.2] 46.0 [5.0] 38.9 [7.3]
IL-10low 40.9 [4.6] 64.4 [5.1] 58.3 [7.6] 59.0 [6.3] 58.4 [8.3]
VT [mL]
SHAM 8.2 [0.4] 8.0 [1.0] 8.0 [1.5] 8.2 [1.3] 7.6 [1.6]
VILI 8.3 [0.7] 4.0 [0.3] 4.0 [0.3] 3.9 [0.5] 4.9 [0.7]
IL-10high 9.0 [0.5] 7.5 [0.7]* 7.4 [0.7]* 7.6 [0.4] 7.7 [0.6]
IL-10low 8.3 [0.7] 6.5 [2.0] 6.7 [2.1] 7.1 [2.0] 6.7 [1.8]
MAP [Torr]
SHAM 138.0 [9.5] 123.0 [11.0] 115.0 [10.0] 120.0 [13.0] 120.0 [9.0]
VILI 147.0 [5.5] 88.5 [19.4] 46.0 [5.0] 60.0 [5.0] 58.5 [1.8]
IL-10high 142.0 [8.0] 115.5 [8.8] 119.0 [11.6] 121.5 [11.0] 125.0 [8.8]
IL-10low 132.0 [8.0] 112.5 [15.9] 123.5 [12.1] 124.5 [15.5] 108.5 [21.1]
pH
SHAM 7.50 [0.03] 7.47 [0.02] 7.44 [0.04] 7.41 [0.03] 7.40 [0.02]
VILI 7.43 [0.04] 7.20 [0.06] 7.26 [0.09] 7.24 [0.02] 7.24 [0.01]
IL-10high 7.51 [0.02] 7.39 [0.04]* 7.36 [0.04] 7.33 [0.04] 7.36 [0.05]
IL-10low 7.46 [0.04] 7.25 [0.04] 7.23 [0.03] 7.28 [0.02] 7.29 [0.05]
Values shown as median (semi-IQR); *p< 0.05 vs. VILI. Due to the high mortality statistical tests were only performed at the following
time-points: baseline (BL), 1 h and 2 h after VILI induction.
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lung. In contrast to the widely-used concept of intra-
tracheal instillation of therapeutics aerosol production and
delivery with specific nebulizers has the advantage that
inhaled aerosol particles deposit in a more equal pattern
and with less individual variation.20 Furthermore, the use of
a nebulizer for the administration of a liquid drug is closer
to the clinical situation.Figure 3 Representative histological lung tissue sections
(magnification 400, hematoxylin and eosin-stained). Lungs
were inflated with the individual mean tidal volume before
fixation. Perivascular and interstitial edema, inflammatory cell
infiltration, intra-alveolar hemorrhage, atelectasis and disor-
ganization of lung architecture can be detected in the lungs of
VILI animals. The lungs of the IL-10-treated animals show
almost normal lung architecture and only minor signs of
pulmonary edema and cell influx.Inhalation of IL-10 prior to VILI induction attenuated the
concentration of the chemotactic cytokine MIP-2 and the
early proinflammatory cytokine IL-1b in BALF and plasma.
Various experimental models ranging from mechanically
stressed cell systems21 to isolated lungs,22 intact
animals14,23,24 and humans1,25 support the importance of
lung-born cytokines in the pathogenesis of VILI. Moreover,
biotrauma is not limited to the lungs but via a spillover of
inflammatory mediators and the activation of immuno-
competent cells in the systemic circulation, may also
initiate and support a systemic inflammatory reaction.26,27
Thus far, in most animal studies the so-called ‘‘two-hit’’
models were used. In these experiments, the lungs are
predamaged by surfactant depletion or tracheal instillation
of endotoxin before the application of baro-/volutrauma.
Imai et al.28 showed in a saline-lavage rabbit model that the
intratracheal instillation of anti-TNF-a antibody prior to the
initiation of conventional mechanical ventilation resulted
in less severe histological lung injury and preserved
oxygenation. In this two-hit model, 4 h of ventilation with
a peak airway pressure of 25 cmH2O and PEEPZ 5 are
sufficient to cause pulmonary edema, infiltration of
neutrophils and hyaline membrane formation. In a similar
lung lavage model, IL-1 receptor antagonist (IL-1RA) pre-
treatment reduced endothelial albumin permeability and
Figure 4 Concentration of MIP-2 and IL-1b in bronchoalveolar lavage fluid (BALF) and plasma of animals that survived at least 2 h
after VILI induction (SHAM, nZ 9; VILI, nZ 7; IL-10high, nZ 8; IL-10low, nZ 4). Median (semi-IQR); *p< 0.05 vs. VILI.
468 S. Hoegl et al.neutrophil infiltration in the lung caused by hyperoxia and
high-pressure ventilation for 8 h.29
However, the role of proinflammatory mediators in the
course of VILI is still controversial, as several in vitro and in
vivo models of VILI have shown inconsistencies in cytokine
response.15 Therefore, in order to isolate possible specific
inflammatory effects of mechanical stress, in the present
study, we tried to eliminate interference from an additional
source of inflammation by using a one-hit model. We are
aware of the contrary clinical situation where VILI is mostly
a complication in critically ill patients who suffer from
pneumonia, sepsis and/or acute respiratory distress
syndrome (ARDS). However, it is not possible to reflect the
complex pathology and clinical pattern of VILI in an animal
model; so we decided in favor of a more or less ‘‘simple’’
VILI model with focus on baro- and atelectotrauma.
IL-10 reduced the pulmonary expression of the stress
markers MMP-9 and HSP-70 and the nitric oxide production
in macrophages, which is an important marker ofFigure 5 HSP-70 detection in the lung homogenates by
Western blot analysis; two representative animals per group.macrophage activation.30 The latter can be relevant, since
reactive nitrogen species can cause tissue damage and
exhaled breath condensate NO2-concentration is directly
correlated to the extent of lung injury.31
HSP-70 is regarded as a marker for pulmonary stress, and
high-pressure ventilation leads to the induction of pulmo-
nary HSP-70 expression.16,24 On the other hand, HSP-70, as
a ‘‘molecular chaperone’’, has anti-inflammatory and
protective properties if induced before stressful stimuli or
mechanical stretch by refolding and stabilizing damaged
intracellular proteins.32 Chen et al.33 postulated that these
paradoxical and contradictory effects may result from the
different functions of intracellular vs. extracellular HSPs
and that extracellular HSPs released from cells with
compromised integrity may function as danger signals.
Matrix metalloproteinases (MMPs) are a group of zinc
enzymes responsible for the degradation of extracellular
matrix components and therefore play a significant role in
embryogenesis and remodeling. However, exuberant orFigure 6 Gelatine zymography of BALF specimens from two
animals per group.
IL-10 reduces biotrauma and mortality in VILI 469aberrant expression of MMPs can cause tissue damage and
has been associated with a variety of lung diseases.34
Whereas MMP-2 is expressed constitutively by a number of
cells, MMP-9 is produced mainly in inflammatory cells,
including neutrophils and alveolar macrophages35 and
MMP-9 had been postulated to participate in neutrophil
transmigration.36 Thus, through down regulation of
neutrophil-mediated inflammation, the inhibition of MMP-9
protects against the development of VILI.36 In addition,
pre-treatment with the MMP inhibitor Primostat attenuated
experimental lung injury caused by high-volume ventila-
tion.35 IL-10 is able to decrease MMP biosynthesis in human
mononuclear phagocytes,37 and in a model of LPS-induced
lung injury IL-10 was able to reduce MMP-9 activity and
neutrophil influx in the lung.38 It can be speculated if in our
model IL-10 directly influenced the activity of MMP-9 in the
lung, thus resulting in reduced tissue damage.
A limitation of this study is that we only tested
prophylactic nebulization of IL-10. In the early state of VILI,
the balance between pro- and anti-inflammatory mediators
is shifted to the proinflammatory side, but possibly in the
later phase of acute lung injury this imbalance may change.
We can only speculate whether in the advanced states of
VILI, IL-10 would still be capable to improve outcome.
Furthermore, as our study focuses on the early changes
after mechanical trauma, it does not answer the question
whether IL-10 prevents long-term effects like chronical
inflammatory reaction or lung fibrosis.
Animal models provide an essential method for exploring
mechanisms and potential new therapies in a proof-of-prin-
ciple fashion.39 The promising results from our study may
support the adoption of IL-10 aerosol in further studies in the
future. It has already been shown in healthy volunteers that
single or multiple doses of IL-10 administered by the intra-
venous or subcutaneous route are safe and show only mild
adverse effects like flu-like symptoms as fever, headache
and myalgia at high dosage.40e42 Even in a small study in
patients with acute lung injury IL-10 administration showed
no notable adverse side effects.43 Furthermore, IL-10 seems
to play an important role in the pathogenesis of arterio-
sclerosis and may be able to stabilize and prevent athero-
sclerotic plaques.44 On the other hand, IL-10 may have
opposed effects by enhancing foam cell formation. It can
only be speculated about how intrapulmonal IL-10 deposition
may affect the pulmonary vascular system in this context.
The heterogeneity and complexity of the clinical picture
of patients with acute lung injury make it difficult to find
a universal, safe and effective pharmacological therapy.
Only larger clinical studiesmay prove the safety and potency
of IL-10 in immunosuppressed critically ill patients who are
suffering from sepsis and additional comorbidities and are
treated under intensive care conditions. Several pharmaco-
logic therapies, such as corticosteroids, surfactant and nitric
oxide, have already been demonstrated to be ineffective in
improving the outcome in acute lung injury in larger clinical
studies, despite promising data from animal studies.39Conclusions
The prophylactic inhalation of IL-10 prior to the induction
of ventilator-induced lung injury (VILI) was able to reducethe pulmonary and systemic stress-response in a dose-
dependent manner. The lungs of the IL-10-treated animals
showed less macroscopic and histological impairment and
less alterations in gas exchange. Moreover, by limiting
pulmonary biotrauma, IL-10 was able to reduce mortality in
experimental VILI. Especially in VILI, where the inflamma-
tory stress reaction is activated in the lung, intrapulmonary
application of anti-inflammatory and immune-modulating
drugs per inhalationem may be very useful.
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